Clinical observation of nanocrystalline injection of tranexamic acid serum combined with photoelectric synergistic technology in the treatment of stable chloasma and its effect on oxidative stress

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070835

Enrollment

Unknown

Registered

2023-04-24

Start date

2020-01-01

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chloasma

Interventions

nano-microneedle group:nano-microneedle

ELOS group:ELOS

combination group :combination treatment

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for stable chloasma ; 2. Age between 18 and 60 years old.

Exclusion criteria

Exclusion criteria: 1.Patients with active chloasma; 2.Patients with infectious diseases such as herpes simplex or flat warts on the face; 3.Patients who are pregnant or breastfeeding; 4.Patients with chronic liver or kidney diseases, cardiovascular or cerebrovascular diseases, or blood system diseases; Those with mental disorders or nervous system diseases; 6. Those who have used other oral or external depigmentation drugs within 1 month; 7. Those who cannot tolerate photoelectric synergistic therapy or are allergic to tranexamic acid essence; 8.Failure to complete treatment or interview as required.

Design outcomes

Primary

Measure	Time frame
malondialdehyde,MDA;superoxide dismutase SOD;glutathione peroxidase GSH-Px;	—

Countries

China

Contacts

Public ContactPan Tingmeng

Maanshan Shiqiye Hospital

pantingmeng@163.com+86 18705556399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026